Evidence map›Paper›PMID 40589098›Full record

ArticleThe oncologist2026

Impact of molecular tumor board on clinical outcomes in patients with refractory solid tumors: a real-world study.

Yan Ling, Xiao-Dong Jiao, Bao-Dong Qin, Jiang-Shui Ding, Zhan Wang, Ke Liu, Wen-Xing Qin, Ying Wu, Li- Sun, Dong-Min Shi and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yan LingDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, 200072, China.ORCID 0009-0005-4057-8987
Xiao-Dong JiaoDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, 200072, China.
Bao-Dong QinDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, 200072, China.
Jiang-Shui DingDepartment of Orthopaedics, Qingyang County People's Hospital, Anhui, 242800, China.
Zhan WangDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, 200072, China.
Ke LiuDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, 200072, China.
Wen-Xing QinDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, 200072, China.
Ying WuDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, 200072, China.
Li- SunDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, 200072, China.
Dong-Min ShiDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, 200072, China.
Shi-Qi ChenDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, 200072, China.
Xue ZhongDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, 200072, China.
Xiao-Peng DuanDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, 200072, China.
Bing LiBurning Rock, Department of Medical, Biotech, Guangzhou, 510300, China.
Yuan-Sheng ZangDepartment of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, 200072, China.

Funding

Chinese National Natural Science Funding 82172710
6 · The paper itself

Abstract

introductionProviding precise oncologic treatment for patients with refractory solid tumors is still an unmet need in clinical practice. This study aimed to assess whether treatments recommended by a molecular tumor board (MTB) can improve clinical outcomes in patients with refractory solid tumors.

methodsWe screened all patients with refractory solid tumors during the period from 2017 to 2022 at the authors' center. The patients with actionable molecular alterations (mainly including druggable tier 2 genetic variants identified using next-generation sequencing [NGS]) were presented to MTB. We compared the overall survival (OS) and progression-free survival (PFS) between the patients treated with a matched therapy recommended by MTB and those who did not receive the MTB-recommended therapy. Patients with no actionable molecular alterations served as an additional control.

resultsA total of 338 patients with refractory solid tumors were screened. Among the 305 patients for whom NGS testing was conducted, 217 patients available for survival outcomes were included in the final analysis. A total of 129 patients had at least one actionable molecular alteration and were presented to MTB; 82 received the MTB-recommended therapy, while the remaining 47 did not. Those who received the recommended therapy had significantly longer median OS (17.7 vs. 4.4 months; HR 0.31, 95% CI: 0.14-0.66; P < .001) and median PFS (7.0 vs. 2.3 months, HR 0.32, 95% CI: 0.16-0.65; P < .001).

conclusionsMTB improves oncologic prognosis in patients with refractory solid tumors, and matching MTB-recommended therapy is an independent factor for OS and PFS.

Indexed as

NeoplasmsAdultAgedFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedPrognosisTreatment Outcomemolecular tumor boardnext-generation sequencingprognosisrefractory solid cancer

Identifiers

PMID40589098
PMCPMC13142151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.